Solid Biosciences Income Statement (2017-2026) | SLDB

Income Statement Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue (Quarter)
6.17M
Operating items
Research & Development (Quarter)
15.51M14.43M14.60M19.95M23.18M14.01M21.29M24.63M19.78M16.70M15.45M18.87M19.46M27.33M30.77M30.91M32.41M38.86M38.13M46.14M
Selling, General & Administrative (Quarter)
6.77M7.14M7.21M7.35M6.85M7.13M7.62M7.40M7.13M6.41M6.81M7.99M8.33M7.86M9.13M9.14M9.28M9.20M11.27M11.17M
Restructuring Costs (Quarter)
1.52M5.66M-0.06M
Operating Expenses (Quarter)
22.28M21.57M21.81M27.30M31.55M21.13M34.57M32.03M26.84M23.11M22.27M26.86M27.79M35.18M39.90M40.05M41.69M48.06M49.40M57.31M
Operating Income (Quarter)
-18.68M-18.03M-18.65M-25.37M-25.38M-21.13M-34.57M-32.03M-26.84M-23.11M-22.27M-26.86M-27.79M-35.18M-39.90M-40.05M-41.69M-48.06M-49.40M-57.31M
EBIT (Quarter)
-18.68M-18.03M-18.65M-25.37M-25.38M-21.13M-34.57M-32.03M-26.84M-23.11M-22.27M-26.86M-27.79M-35.18M-39.90M-40.05M-41.69M-48.06M-49.40M-57.31M
Non-operating items
Non Operating Investment Income (Quarter)
-1.65M-0.90M-0.85M-2.65M-1.65M
Interest & Investment Income (Quarter)
-0.01M0.05M0.29M0.73M1.53M1.80M2.06M1.96M1.76M2.65M2.56M2.33M1.93M2.30M2.97M2.59M2.05M2.06M
Other Non Operating Income (Quarter)
0.00M-0.01M-0.00M-0.01M-0.35M0.28M0.27M0.28M0.27M0.00M0.24M0.21M0.20M0.19M0.21M0.21M0.22M0.16M
Non Operating Income (Quarter)
-0.01M0.05M-0.02M0.04M-0.00M0.72M19.41M1.96M2.21M2.13M-5.21M2.56M0.24M2.46M-2.70M0.19M0.21M2.28M4.28M0.57M
Net income details
EBT (Quarter)
-18.70M-18.03M-18.65M-25.32M-25.09M-20.40M-33.03M-30.35M-24.89M-21.26M-20.61M-24.31M-25.31M-32.94M-38.05M-37.82M-38.79M-45.14M-47.36M-55.24M
Profit After Tax (Quarter)
-18.70M-17.98M-18.61M-25.33M-25.09M-20.41M-15.15M-30.07M-24.63M-20.98M-20.32M-24.30M-25.07M-32.73M-42.60M-39.28M-39.48M-45.78M-49.76M-56.74M
Income from Non-Controlling Interests (Quarter)
Income from Continuing Operations (Quarter)
-18.70M-18.03M-18.65M-25.32M-25.09M-20.40M-33.03M-30.35M-24.89M-21.26M-20.61M-24.31M-25.31M-32.94M-38.05M-37.82M-38.79M-45.14M-47.36M-55.24M
Consolidated Net Income (Quarter)
-18.70M-18.03M-18.65M-25.32M-25.09M-20.40M-33.03M-30.35M-24.89M-21.26M-20.61M-24.31M-25.31M-32.94M-38.05M-37.82M-38.79M-45.14M-47.36M-55.24M
Income towards Parent Company (Quarter)
-18.70M-18.03M-18.65M-25.32M-25.09M-20.40M-33.03M-30.35M-24.89M-21.26M-20.61M-24.31M-25.31M-32.94M-38.05M-37.82M-38.79M-45.14M-47.36M-55.24M
Preferred Dividend Payments (Quarter)
Net Income towards Common Stockholders (Quarter)
-18.70M-18.03M-18.65M-25.32M-25.09M-20.40M-33.03M-30.35M-24.89M-21.26M-20.61M-24.31M-25.31M-32.94M-38.05M-37.82M-38.79M-45.14M-47.36M-55.24M
Additional items
EPS (Basic) (Quarter)
-0.17-2.40-2.46-3.37-3.33-2.71-0.68-1.54-1.25-1.05-1.00-0.64-0.61-0.79-1.02-0.59-0.42-0.48-0.53-0.52
EPS (Weighted Average and Diluted) (Quarter)
-0.17-2.40-2.46-3.37-3.33-2.71-0.68-1.54-1.25-1.05-1.00-0.64-0.61-0.79-1.02-0.59-0.42-0.48-0.53-0.52
Shares Outstanding (Weighted Average) (Quarter)
112.30M6.98M7.12M7.51M7.52M7.53M8.51M19.57M19.62M19.77M19.88M38.16M40.93M40.18M40.82M66.34M94.14M94.42M87.50M109.81M
Shares Outstanding (Diluted Average) (Quarter)
100.85M7.49M7.12M7.51M7.52M7.53M8.51M19.57M19.66M20.06M19.88M38.16M39.54M41.44M40.82M66.34M94.14M85.07M87.50M109.81M
EBITDA (Quarter)
-18.71M-17.99M-18.65M-25.33M-25.16M-20.48M-34.57M-30.00M-26.84M-23.11M-22.27M-26.86M-27.79M-35.18M-39.90M-40.05M-41.69M-48.06M-49.40M-56.80M
Interest Expenses (Quarter)
0.12M0.11M0.11M0.10M0.10M0.09M0.08M0.07M0.07M0.06M-0.34M0.01M